{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T09:49:24Z","timestamp":1724147364667},"reference-count":33,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2016,3,14]],"date-time":"2016-03-14T00:00:00Z","timestamp":1457913600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100001773","name":"University of New South Wales","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001773","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2016,9]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>The aim of the study was to compare the efficacy and safety of rosuvastatin initiation with those of switching of ritonavir\u2010boosted protease inhibitors (<jats:styled-content style=\"fixed-case\">PI<\/jats:styled-content>\/rs) in <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\u20101\u2010infected adults with hypercholesterolaemia and increased cardiovascular risk scores.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this open\u2010label, multicentre study, <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\u20101\u2010infected adults on <jats:styled-content style=\"fixed-case\">PI<\/jats:styled-content>\/r\u2010based therapy with viral load &lt; 50 <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\u20101 <jats:styled-content style=\"fixed-case\">RNA<\/jats:styled-content> copies\/<jats:styled-content style=\"fixed-case\">mL<\/jats:styled-content>, fasting total cholesterol \u2265 5.5 mmol\/L (both for \u2265 6 months) and elevated cardiovascular risk (Framingham score \u2265 8% or diabetes or family history), and not on lipid\u2010lowering therapy, were randomized to open\u2010label rosuvastatin 10 mg\/day or to <jats:styled-content style=\"fixed-case\">PI<\/jats:styled-content>\/r switching, both with standardized diet\/exercise advice. The primary endpoint was change in total cholesterol at week 12 (intention to treat).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were 43 participants (23 on rosuvastatin). Baseline characteristics were: mean [\u00b1 standard deviation (<jats:styled-content style=\"fixed-case\">SD<\/jats:styled-content>)] age 55 (8.5) years, 42 (98%) male, 41 (95%) white race, and mean (\u00b1 <jats:styled-content style=\"fixed-case\">SD<\/jats:styled-content>) total cholesterol 6.2 (1.2) mmol\/L. At enrolment, <jats:styled-content style=\"fixed-case\">PI<\/jats:styled-content>\/rs were lopinavir\/ritonavir (<jats:italic>n<\/jats:italic> = 22; 51%), atazanavir\/ritonavir (<jats:italic>n<\/jats:italic> = 12; 28%) and darunavir\/ritonavir (<jats:italic>n<\/jats:italic> = 9; 21%). The commonest <jats:styled-content style=\"fixed-case\">PI<\/jats:styled-content>\/r substitutes were raltegravir (<jats:italic>n<\/jats:italic> = 9; 45%) and rilpivirine (<jats:italic>n<\/jats:italic> = 4; 20%). All participants were adherent through to week 12. Rosuvastatin yielded greater declines than <jats:styled-content style=\"fixed-case\">PI<\/jats:styled-content>\/r switching in total (\u2212 21.4% <jats:italic>vs<\/jats:italic>. \u2212 8.7%, respectively; <jats:italic>P<\/jats:italic> = 0.003) and low\u2010density lipoprotein (\u2212 29.9% <jats:italic>vs<\/jats:italic>. \u2212 1.0%, respectively; <jats:italic>P<\/jats:italic> &lt; 0.001) cholesterol, but smaller declines in very low\u2010density lipoprotein cholesterol and triglycerides (<jats:italic>P<\/jats:italic> &lt; 0.01). Cholesterol lowering was greater in participants on atazanavir\/ritonavir or once\u2010daily darunavir\/ritonavir (<jats:italic>vs<\/jats:italic>. lopinavir\/ritonavir). More study drug\u2010related adverse events (mostly grade 1 nausea\/diarrhoea; 10 <jats:italic>vs<\/jats:italic>. one, respectively; <jats:italic>P<\/jats:italic> = 0.001) occurred with <jats:styled-content style=\"fixed-case\">PI<\/jats:styled-content>\/r switching than with rosuvastatin.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In adults receiving a <jats:styled-content style=\"fixed-case\">PI<\/jats:styled-content>\/r, rosuvastatin 10 mg\/day for 12 weeks yielded larger decreases in total and low\u2010density lipoprotein cholesterol than <jats:styled-content style=\"fixed-case\">PI<\/jats:styled-content>\/r switching, and was better tolerated.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hiv.12362","type":"journal-article","created":{"date-parts":[[2016,3,18]],"date-time":"2016-03-18T11:54:52Z","timestamp":1458302092000},"page":"605-614","source":"Crossref","is-referenced-by-count":11,"title":["Rosuvastatin <i>vs<\/i>. protease inhibitor switching for hypercholesterolaemia: a randomized trial"],"prefix":"10.1111","volume":"17","author":[{"given":"FJ","family":"Lee","sequence":"first","affiliation":[{"name":"Clinical Research Program Centre for Applied Medical Research, St Vincent's Hospital Sydney NSW Australia"},{"name":"Sydney Medical School University of Sydney Sydney NSW Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Monteiro","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit Hospital Clin\u00edc, University of Barcelona Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Baker","sequence":"additional","affiliation":[{"name":"East Sydney Doctors Sydney NSW Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Bloch","sequence":"additional","affiliation":[{"name":"Holdsworth House Medical Practice Sydney NSW Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Roth","sequence":"additional","affiliation":[{"name":"Prahran Market Clinic Melbourne Vic. Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Finlayson","sequence":"additional","affiliation":[{"name":"Taylor Square Private Clinic Sydney NSW Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Moore","sequence":"additional","affiliation":[{"name":"Northside Clinic Melbourne Vic. Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Hoy","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases The Alfred Hospital &amp; Monash University Melbourne Vic. Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Martinez","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit Hospital Clin\u00edc, University of Barcelona Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Carr","sequence":"additional","affiliation":[{"name":"Clinical Research Program Centre for Applied Medical Research, St Vincent's Hospital Sydney NSW Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,3,14]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.100.7.700"},{"key":"e_1_2_6_3_1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00126334-200001010-00005","article-title":"Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection","volume":"23","author":"Mulligan K","year":"2000","journal-title":"J Acquir Immune Defic Syndr"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1086\/649897"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.7326\/M14-1084"},{"key":"e_1_2_6_6_1","first-page":"CD004816","article-title":"Statins for the primary prevention of cardiovascular disease","volume":"1","author":"Taylor F","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)62041-9"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001240"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328331d2ab"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32833a608a"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000174451.78497.8f"},{"key":"e_1_2_6_12_1","volume-title":"European AIDS Clinical Society (EACS) Guidelines for the Clinical Management and Treatment of HIV\u2010Infected Adults, Version 7.1","author":"European AIDS Clinical Society","year":"2014"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1086\/378131"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.19.2486"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2006.00362.x"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis406"},{"key":"e_1_2_6_17_1","unstructured":"FDA Crestor Prescribing Information. 2014 [updated July 08]."},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181a5701c"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu234"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0010019"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00280883"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32835b2ef1"},{"key":"e_1_2_6_23_1","volume-title":"Guidelines for the Use of Antiretroviral Agents in HIV\u20101\u2010Infected Adults and Adolescents","author":"Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents","year":"2015"},{"key":"e_1_2_6_24_1","unstructured":"Division of AIDS Table for Grading the severity of Adult and Pediatric Adverse events. 2004. [clarification 2009]. Bethesda Maryland USA: National Intsitute of Allergy and Infectious Diseases. Available athttp:\/\/rs.tech-res.com\/safetyandpharmacovigilence\/(accessed 14 December 2014)."},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu012"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000087"},{"key":"e_1_2_6_27_1","unstructured":"MosepeleM ReganS MeigsJB GrinspoonS TriantVA.Application of new ACC\/AHA cholesterol guidelines to an HIV clinical care cohort. 22nd Conference on Retroviruses and Opportunistic Infections. Seattle WA USA February 22\u201325 2015."},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2010.182"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(14)00032-0"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9150(86)90176-0"},{"key":"e_1_2_6_31_1","unstructured":"Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV\u2010Infected Adults (REPRIEVE). Available athttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT02344290(accessed 10 September 2015)."},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0807646"},{"key":"e_1_2_6_33_1","doi-asserted-by":"crossref","unstructured":"SponsellerCA KryzhanovskiVA MorganRE CampbellSE ThompsonMA AbergJA.After 52 weeks pitavastatin is superior to pravastatin for LDL\u2010C lowering in patients with HIV. 21st Conference on Retroviruses and Opportunistic Infections. Boston MA USA March 3 \u2013 6 2014.","DOI":"10.1016\/j.jacl.2014.02.061"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61190-8"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhiv.12362","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.12362","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T19:31:21Z","timestamp":1695497481000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.12362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,14]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["10.1111\/hiv.12362"],"URL":"https:\/\/doi.org\/10.1111\/hiv.12362","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,14]]}}}